Cochrane Kidney and Transplant reviews
Status | Stage |
---|---|
- (a traditional Chinese medicine) for kidney transplant recipients
- Acupuncture and related interventions for symptoms of chronic kidney disease
- Adjunctive medical expulsive therapy for kidney and ureteral stone fragments following shock wave lithotripsy
- Advance care planning for haemodialysis patients
- Aldosterone antagonists for people with chronic kidney disease requiring dialysis
- Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
- Altered dietary salt intake for people with chronic kidney disease
- Altered dietary salt intake for preventing diabetic kidney disease and its progression
- Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function
- Androgens for the anaemia of chronic kidney disease in adults
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients
- Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease
- Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women
- Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis
- Antibiotics for acute pyelonephritis in adults
- Antibiotics for acute pyelonephritis in children
- Antibiotics for asymptomatic bacteriuria
- Antibiotics for asymptomatic bacteriuria in kidney transplant recipients
- Antibiotics for preventing recurrent urinary tract infection in non-pregnant women
- Antibiotics for treating lower urinary tract infection in children
- Antibody induction therapy for lung transplant recipients
- Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease
- Anticoagulation for people receiving long-term haemodialysis
- Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis
- Antifungal agents for preventing fungal infections in solid organ transplant recipients
- Antihypertensive agents for preventing diabetic kidney disease
- Antihypertensive treatment for kidney transplant recipients
- Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
- Antimicrobial agents for treating uncomplicated urinary tract infection in women
- Antimicrobial lock solutions for preventing catheter-related infections in haemodialysis
- Antioxidants for adults with chronic kidney disease
- Antiplatelet agents for chronic kidney disease
- Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
- Aspiration and sclerotherapy versus hydrocoelectomy for treating hydrocoeles
- Astragalus (a traditional Chinese medicine) for treating chronic kidney disease
- Atrial natriuretic peptide for preventing and treating acute kidney injury
- Automated peritoneal dialysis versus continuous ambulatory peritoneal dialysis for people with kidney failureUpdated
- Belatacept for kidney transplant recipients
- Bicarbonate versus lactate solutions for acute peritoneal dialysis
- Bicarbonate- versus lactate-buffered solutions for acute continuous haemodiafiltration or haemofiltration
- Biocompatible dialysis fluids for peritoneal dialysis
- Biocompatible hemodialysis membranes for acute renal failure
- C-reactive protein, procalcitonin, and erythrocyte sedimentation rate for the diagnosis of lower urinary tract infection in older people
- Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients
- Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients
- Calcium channel blockers as medical expulsive therapy for ureteric stones
- Calcium channel blockers for people with chronic kidney disease requiring dialysis
- Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients
- Cardiac testing for coronary artery disease in potential kidney transplant recipients
- Carnitine supplements for people with chronic kidney disease requiring dialysis
- Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis patients
- Catheter type, placement and insertion techniques for preventing catheter-related infections in chronic peritoneal dialysis patients
- Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease
- Chinese herbal medicine for treating recurrent urinary tract infections in women
- Chinese herbal medicine Huangqi type formulations for nephrotic syndrome
- Citrate salts for preventing and treating calcium containing kidney stones in adults
- Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older people
- Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults
- Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
- Continuous renal replacement therapy (CRRT) for rhabdomyolysis
- Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease
- Correction of chronic metabolic acidosis for chronic kidney disease patients
- Corticosteroid therapy for nephrotic syndrome in children
- Cranberries for preventing urinary tract infections
- Cranberries for treating urinary tract infections
- D-mannose for preventing and treating urinary tract infections
- Darbepoetin for the anaemia of chronic kidney disease
- Delayed initiation or reduced initial dose of calcineurin-inhibitors for kidney transplant recipients
- Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis
- Dialysis versus conservative management for stage 5 chronic kidney disease in the elderly
- Dietary interventions for adults with chronic kidney disease
- Dietary interventions for mineral and bone disorder in people with chronic kidney disease
- Dietary interventions for preventing complications in idiopathic hypercalciuria
- Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infections
- Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
- Diuretics for preventing and treating acute kidney injury
- Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage kidney disease
- Duration of antibacterial treatment for uncomplicated urinary tract infection in women
- Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease
- Early versus delayed erythropoietin for the anaemia of end-stage kidney disease
- Early versus late removal of urinary catheter after kidney transplantation
- Early versus late ureteric stent removal after kidney transplantation
- Education programmes for people with chronic kidney disease and diabetes
- Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function
- Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
- eHealth interventions for people with chronic kidney disease
- Emergency interventions for hyperkalaemia
- Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
- Erythropoiesis-stimulating agents for preventing acute kidney injuryNew
- Exercise training for adult kidney transplant recipients
- Exercise training for adult lung transplant recipients
- Exercise training for adults undergoing maintenance dialysis
- Exercise training for adults with chronic kidney disease
- Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi
- Fenoldopam for preventing and treating acute kidney injury
- Fish oil for kidney transplant recipients
- Fluids and diuretics for acute ureteric colic
- Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients
- Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes
- Glucose targets for preventing diabetic kidney disease and its progression
- Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients
- Growth hormone for children with chronic kidney disease
- Gut microbial biomarkers for predicting adverse outcomes in people with chronic kidney disease
- Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease
- Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease
- Heparin and related substances for preventing diabetic kidney disease
- High-flux versus low-flux membranes for end-stage kidney disease
- HMG CoA reductase inhibitors (statins) for dialysis patients
- HMG CoA reductase inhibitors (statins) for kidney transplant recipients
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
- HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
- Home versus in-centre haemodialysis for people with kidney failure
- Hook F (a traditional Chinese medicine) for primary nephrotic syndrome
- Human albumin for intradialytic hypotension in haemodialysis patients
- Human albumin infusion for treating oedema in people with nephrotic syndrome
- Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function
- Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
- Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
- Immunosuppressive agents for treating IgA nephropathy
- Immunosuppressive therapy for IgA nephropathy in children
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome
- Immunosuppressive treatment for proliferative lupus nephritis
- Incremental versus standard dialysis for people with kidney failure
- Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
- Intensity of continuous renal replacement therapy for acute kidney injury
- Interleukin 2 receptor antagonists for kidney transplant recipients
- Intermittent versus continuous renal replacement therapy for acute renal failure in adults
- Interventions for atypical haemolytic uraemic syndrome
- Interventions for BK virus infection in kidney transplant recipients
- Interventions for chronic kidney disease-associated restless legs syndrome
- Interventions for chronic non-hypovolaemic hypotonic hyponatraemia
- Interventions for covert bacteriuria in children
- Interventions for dialysis patients with hepatitis C virus (HCV) infection
- Interventions for erythropoietin-resistant anaemia in dialysis patients
- Interventions for fatigue in people with kidney failure requiring dialysis
- Interventions for focal segmental glomerulosclerosis in adults
- Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura
- Interventions for HIV-associated nephropathy
- Interventions for idiopathic steroid-resistant nephrotic syndrome in children
- Interventions for improving adherence to dietary salt and fluid restrictions in people with chronic kidney disease (stage 4 and 5)
- Interventions for improving health literacy in people with chronic kidney disease
- Interventions for improving sleep quality in people with chronic kidney disease
- Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients
- Interventions for increasing solid organ donor registration
- Interventions for itch in people with advanced chronic kidney disease
- Interventions for lowering plasma homocysteine levels in dialysis patients
- Interventions for lowering plasma homocysteine levels in kidney transplant recipients
- Interventions for metabolic bone disease in children with chronic kidney disease
- Interventions for minimal change disease in adults with nephrotic syndrome
- Interventions for preventing and treating acute kidney injury in children
- Interventions for preventing and treating kidney disease in IgA vasculitis
- Interventions for preventing bone disease in kidney transplant recipients
- Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome
- Interventions for preventing haemodialysis dysequilibrium syndrome
- Interventions for preventing infection in nephrotic syndrome
- Interventions for preventing infectious complications in haemodialysis patients with central venous catheters
- Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseUpdated
- Interventions for preventing thrombosis in solid organ transplant recipients
- Interventions for preventing urinary tract infections in kidney transplant recipients
- Interventions for primary vesicoureteric reflux
- Interventions for renal vasculitis in adults
- Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts
- Interventions for treating antibody-mediated acute rejection in kidney transplant recipients
- Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis
- Interventions for treating central venous haemodialysis catheter malfunction
- Interventions for treating sexual dysfunction in patients with chronic kidney disease
- Interventions for undescended testes in children
- Interventions for weight loss in people with chronic kidney disease who are overweight or obese
- Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury
- Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
- Laparoendoscopic single-site donor nephrectomy (LESS-DN) versus standard laparoscopic donor nephrectomy
- Less intensive versus conventional haemodialysis for people with end-stage kidney disease
- Lipid-lowering agents for nephrotic syndrome
- Long-term antibiotics for preventing recurrent urinary tract infection in children
- Loop diuretics for patients receiving blood transfusions
- Low dialysate sodium levels for chronic haemodialysis
- Low protein diets for non-diabetic adults with chronic kidney disease
- Metformin for preventing the progression of chronic kidney disease
- Methenamine hippurate for preventing urinary tract infections
- Minimally invasive surgical techniques for kidney transplantation
- Modes of administration of antibiotics for symptomatic severe urinary tract infections
- Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients
- Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children
- Non-immunosuppressive treatment for IgA nephropathy
- Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
- Non-steroidal anti-inflammatory drugs for treating symptomatic uncomplicated urinary tract infections in non-pregnant adult women
- Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colic
- Nonsteroidal anti-inflammatory drugs (NSAIDS) versus opioids for acute renal colic
- Normal saline versus lower-chloride solutions for kidney transplantation
- Normothermic and hypothermic machine perfusion preservation versus static cold storage for deceased donor kidney transplantation
- Nutritional support for acute kidney injury
- Oestrogens for preventing recurrent urinary tract infection in postmenopausal women
- Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease
- Oral adsorbents for preventing or delaying the progression of chronic kidney disease
- Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis
- Parenteral versus oral iron therapy for adults and children with chronic kidney disease
- Pentoxifylline for diabetic kidney disease
- Percussion, diuresis, and inversion therapy for the passage of lower pole kidney stones following shock wave lithotripsy
- Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients
- Peritoneal dialysis for acute kidney injury
- Peritoneal dialysis versus haemodialysis for people commencing dialysis
- Pharmacological interventions for heart failure in people with chronic kidney disease
- Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
- Pharmacological interventions for preventing complications in idiopathic hypercalciuria
- Pharmacological interventions for the acute management of hyperkalaemia in adults
- Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D
- Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
- Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
- Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients
- Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
- Pre-emptive correction for haemodialysis arteriovenous access stenosis
- Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
- Pre-emptive versus non pre-emptive kidney transplantation for end-stage kidney disease
- Predictive factors for BK polyomavirus infection in solid organ transplant recipients
- Preoperative vascular access evaluation for haemodialysis patients
- Probiotics for preventing urinary tract infection in people with neuropathic bladder
- Probiotics for preventing urinary tract infections in adults and children
- Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children
- Prostaglandin E1 for preventing the progression of diabetic kidney disease
- Protein restriction for children with chronic kidney disease
- Protein restriction for diabetic kidney disease
- Psychosocial interventions for preventing and treating depression in dialysis patients
- Quinolones for uncomplicated acute cystitis in women
- Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis
- Rheum officinale (a traditional Chinese medicine) for chronic kidney disease
- Robotic versus laparoscopic versus open nephrectomy for live kidney donors
- Routine intraoperative ureteric stenting for kidney transplant recipients
- Screening with urinary dipsticks for reducing morbidity and mortality
- Serum and urine nucleic acid screening tests for polyomavirus-associated nephropathy in kidney and kidney-pancreas transplant recipients
- Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation
- Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children
- Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients
- Sodium bicarbonate supplements for treating acute kidney injury
- Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
- Steroid avoidance or withdrawal for kidney transplant recipients
- Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients
- Synbiotics, prebiotics and probiotics for people with chronic kidney disease
- Synbiotics, prebiotics and probiotics for solid organ transplant recipients
- Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients
- Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients
- Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
- Teicoplanin versus vancomycin for proven or suspected infection
- Therapeutic donor hypothermia following brain death to improve the quality of transplanted organs
- Thiazolidinediones for people with chronic kidney disease and diabetes
- Thyroid hormones for acute kidney injury
- Tidal versus other forms of peritoneal dialysis for acute kidney injury
- Timing of kidney replacement therapy initiation for acute kidney injury
- Transplantation versus other therapies for patients with polycystic liver disease
- Treatment for hepatitis C virus-associated mixed cryoglobulinaemia
- Treatment for peritoneal dialysis-associated peritonitis
- Ultrasound use for the placement of haemodialysis catheters
- Upper limb exercise for arteriovenous fistula maturation in people requiring permanent haemodialysis access
- Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease
- Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease
- Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease
- Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women
- Vitamin B and its derivatives for diabetic kidney disease
- Vitamin D compounds for people with chronic kidney disease not requiring dialysis
- Vitamin D compounds for people with chronic kidney disease requiring dialysis
- Blood pressure targets in people with cardiovascular disease
- Central venous catheter coating with antiseptics or antibiotics for reducing catheter-related infections in adults
- Discharge planning from hospital
- Does heparin locking prevent blocking of central venous catheters in adults when compared to locking with normal saline?
- Dressings for the prevention of surgical site infection
- Early and late adverse effects on the kidney after treatment for childhood cancer
- Effect of decision-support tools on mobile phones on primary health care
- End-of-life care pathways for the dying
- Exercise interventions for adults after liver transplantation
- Exercise-based cardiac rehabilitation for patients following a heart transplantation
- Follow-up services to improve the long-term after-effects of a stay in the intensive care unit
- Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
- Hepatitis B immunisation for adults with end-stage kidney disease
- Hepatitis B vaccines achieve antibody production in patients with chronic renal failure, but we do not know if the vaccines are protective
- Home-based end-of-life care
- How often should dressings on central venous access devices (CVADs) be changed to reduce catheter-related infection?
- Improving outcomes for people with multiple chronic conditions
- Interventions for preventing of non-melanoma skin cancers in high-risk groups
- Interventions for preventing recurrent urinary tract infections during pregnancy
- Interventions for the management of dry mouth: topical therapies
- Interventions to improve people's drug-taking behaviour with lipid-lowering drugs
- Measurement of serum galactomannan to detect invasive aspergillosis in immunocompromised patients
- Medical interventions to prevent early graft rejection after liver transplantation
- Medical interventions to prevent graft rejection after liver transplantation
- Medicines to prevent blockage of vascular access following surgery for formation of arteriovenous fistula or graft
- Newborn circumcision for the prevention of urinary tract infections in infancy
- Non-drug treatments for dry mouth symptoms
- Opiods for restless legs syndrome
- Protein restriction for diabetic renal disease
- Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes
- Shared care across the interface between primary and specialty care in chronic disease management
- Skin antisepsis for reducing central venous catheter-related infections
- Surgical hand antisepsis to reduce surgical site infection
- The effect of a low salt diet on blood pressure and some hormones and lipids in people with normal and elevated blood pressure
- Treatment for Anderson-Fabry disease
- ACUTE KIDNEY INJURY (25)
- Anticoagulation (1)
- Antihypertensive agents (0)
- Atrial natriuretic peptide (1)
- Contrast-induced nephropathy (0)
- Diuretics (1)
- Dopamine and dopamine antagonists (1)
- Erythropoiesis-stimulating agents (1)
- Growth factors (0)
- Haemolytic uraemic syndrome (3)
- Hyperkalaemia (2)
- Nutrition (1)
- Plasma volume expanders (0)
- Post cardiac surgery (1)
- Kidney replacement therapy (9)
- Bicarbonate- versus lactate-buffered solutions for acute continuous haemodiafiltration or haemofiltration
- Intensity of continuous renal replacement therapy for acute kidney injury
- Intermittent versus continuous renal replacement therapy for acute renal failure in adults
- Continuous renal replacement therapy (CRRT) for rhabdomyolysis
- Peritoneal dialysis for acute kidney injury
- Biocompatible hemodialysis membranes for acute renal failure
- Tidal versus other forms of peritoneal dialysis for acute kidney injury
- Timing of kidney replacement therapy initiation for acute kidney injury
- Bicarbonate versus lactate solutions for acute peritoneal dialysis
- Prevention and Treatment (1)
- Sodium bicarbonate supplements (1)
- Statins (1)
- Thyroid hormones (1)
- CHRONIC KIDNEY DISEASE (93)
- General management (53)
- Acidosis control (1)
- Anaemia control (9)
- Androgens for the anaemia of chronic kidney disease in adults
- Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
- Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
- Darbepoetin for the anaemia of chronic kidney disease
- Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis
- Parenteral versus oral iron therapy for adults and children with chronic kidney disease
- Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease
- Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients
- Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
- Antihypertensive agents (4)
- Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease
- Blood pressure targets in people with cardiovascular disease
- Calcium channel blockers for people with chronic kidney disease requiring dialysis
- Bone and mineral disease (6)
- Dietary interventions for mineral and bone disorder in people with chronic kidney disease
- Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients
- Interventions for metabolic bone disease in children with chronic kidney disease
- Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D
- Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
- Vitamin D compounds for people with chronic kidney disease not requiring dialysis
- Cardiovascular risk management (8)
- Altered dietary salt intake for people with chronic kidney disease
- Antioxidants for adults with chronic kidney disease
- Antiplatelet agents for chronic kidney disease
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
- Pharmacological interventions for heart failure in people with chronic kidney disease
- Interventions for improving adherence to dietary salt and fluid restrictions in people with chronic kidney disease (stage 4 and 5)
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
- Interventions for weight loss in people with chronic kidney disease who are overweight or obese
- Endocrine - other (3)
- Lifestyle and complimentary therapies (7)
- Alternate therapies (4)
- Acupuncture and related interventions for symptoms of chronic kidney disease
- Astragalus (a traditional Chinese medicine) for treating chronic kidney disease
- Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease
- Rheum officinale (a traditional Chinese medicine) for chronic kidney disease
- Exercise (2)
- Psychosocial (1)
- Alternate therapies (4)
- Nutrition (7)
- Altered dietary salt intake for people with chronic kidney disease
- Dietary interventions for adults with chronic kidney disease
- Low protein diets for non-diabetic adults with chronic kidney disease
- Synbiotics, prebiotics and probiotics for people with chronic kidney disease
- Protein restriction for children with chronic kidney disease
- The effect of a low salt diet on blood pressure and some hormones and lipids in people with normal and elevated blood pressure
- Interventions for weight loss in people with chronic kidney disease who are overweight or obese
- Other (8)
- Effect of decision-support tools on mobile phones on primary health care
- eHealth interventions for people with chronic kidney disease
- Interventions for improving health literacy in people with chronic kidney disease
- Interventions for improving sleep quality in people with chronic kidney disease
- Treatment for hepatitis C virus-associated mixed cryoglobulinaemia
- Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease
- Oral adsorbents for preventing or delaying the progression of chronic kidney disease
- Interventions for itch in people with advanced chronic kidney disease
- Genetic disorders (3)
- Anderson-Fabry disease (1)
- Cystinosis (0)
- Polycystic kidney disease (2)
- Glomerular diseases (35)
- Diabetic kidney disease (17)
- Alternate therapies (0)
- Dietary interventions (4)
- Education programmes (1)
- Pharmacological interventions (12)
- Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease
- Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes
- Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
- Antihypertensive agents for preventing diabetic kidney disease
- Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes
- Glucose targets for preventing diabetic kidney disease and its progression
- Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients
- Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
- Pentoxifylline for diabetic kidney disease
- Prostaglandin E1 for preventing the progression of diabetic kidney disease
- Heparin and related substances for preventing diabetic kidney disease
- Thiazolidinediones for people with chronic kidney disease and diabetes
- Focal segmental glomerulosclerosis (1)
- HIV-associated nephropathy (1)
- Henoch-Schönlein Purpura (HSP) (1)
- IgA nephropathy (3)
- Lupus nephritis (1)
- Membranoproliferative glomerulonephritis (0)
- Membranous nephropathy (1)
- Minimal change nephropathy (1)
- Nephrotic syndrome (8)
- Chinese herbal medicine Huangqi type formulations for nephrotic syndrome
- Human albumin infusion for treating oedema in people with nephrotic syndrome
- Interventions for idiopathic steroid-resistant nephrotic syndrome in children
- Lipid-lowering agents for nephrotic syndrome
- Interventions for preventing infection in nephrotic syndrome
- Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children
- Hook F (a traditional Chinese medicine) for primary nephrotic syndrome
- Corticosteroid therapy for nephrotic syndrome in children
- Rapidly progressive glomerulonephritis (1)
- Diabetic kidney disease (17)
- Investigations, procedures and process of care (1)
- Kidney biopsies (0)
- Referral strategies (1)
- Prognosis reviews (1)
- General management (53)
- DIAGNOSTIC TEST ACCURACY REVIEWS (5)
- Acute pyelonephritis (1)
- cytomegalovirus (CMV) diagnostic tests (0)
- Iron measurements (0)
- Other (1)
- Renal scarring (0)
- Suprapubic urine aspiration (0)
- Transplantation (2)
- Vesicoureteric reflux (1)
- Ureteric colic (0)
- DRUGS AND THE KIDNEY (7)
- Early and late adverse effects on the kidney after treatment for childhood cancer
- Effects of peri-operative nonsteroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function
- Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function
- Loop diuretics for patients receiving blood transfusions
- Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function
- Teicoplanin versus vancomycin for proven or suspected infection
- Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function
- DRUGS: OTHER (1)
- ELECTROLYTE DISORDERS (2)
- KIDNEY FAILURE / END-STAGE KIDNEY DISEASE (73)
- General management (33)
- Biochemical control (0)
- Acidosis (0)
- Potassium (0)
- Anaemia control (3)
- Antihypertensive agents (0)
- Bone and mineral disease (1)
- Cardiovascular risk management (3)
- Aldosterone antagonists (1)
- Cholesterol (1)
- Homocysteine (1)
- Endocrine - other (0)
- Anabolic steroids (0)
- Sex hormones (0)
- Infection (6)
- Dressings for the prevention of surgical site infection
- Hepatitis B immunisation for adults with end-stage kidney disease
- Hepatitis B vaccines achieve antibody production in patients with chronic renal failure, but we do not know if the vaccines are protective
- How often should dressings on central venous access devices (CVADs) be changed to reduce catheter-related infection?
- Interventions for dialysis patients with hepatitis C virus (HCV) infection
- Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
- Lifestyle and complimentary therapies (3)
- Alternate therapies (0)
- Exercise (1)
- Other (0)
- Psychosocial (2)
- Nutrition (3)
- Carnitine supplements for people with chronic kidney disease requiring dialysis
- Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis
- The effect of a low salt diet on blood pressure and some hormones and lipids in people with normal and elevated blood pressure
- Other (6)
- Cramps (0)
- Dry mouth (2)
- Fatigue (1)
- Pruritus (itching) (1)
- Restless legs (2)
- Treatment options (8)
- Conservative management (1)
- Dialysis (5)
- Incremental versus standard dialysis for people with kidney failure
- Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults
- Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease
- Peritoneal dialysis versus haemodialysis for people commencing dialysis
- Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease
- Palliative care (1)
- Transplantation (1)
- Biochemical control (0)
- Haemodialysis (30)
- Access (8)
- Catheters (2)
- Contrast agents (0)
- Fluid control (0)
- Needling devices (0)
- Vascular access (6)
- Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease
- Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease
- Medicines to prevent blockage of vascular access following surgery for formation of arteriovenous fistula or graft
- Pre-emptive correction for haemodialysis arteriovenous access stenosis
- Preoperative vascular access evaluation for haemodialysis patients
- Ultrasound use for the placement of haemodialysis catheters
- Anticoagulation (3)
- Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease
- Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
- Anticoagulation for people receiving long-term haemodialysis
- Dialysate (2)
- Dialysers (2)
- Dialyser reuse (0)
- Dual dialysers (0)
- Membranes (2)
- Ultrafiltration control (0)
- Haemodialysis delivery (3)
- Dose / duration (1)
- Kt/V and creatinine clearance targets (0)
- Treatment options (2)
- Infection - prevention and treatment (7)
- Antimicrobial lock solutions for preventing catheter-related infections in haemodialysis
- Central venous catheter coating with antiseptics or antibiotics for reducing catheter-related infections in adults
- Dressings for the prevention of surgical site infection
- Interventions for preventing infectious complications in haemodialysis patients with central venous catheters
- Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis
- Skin antisepsis for reducing central venous catheter-related infections
- Surgical hand antisepsis to reduce surgical site infection
- Other (3)
- Thrombosis / patency (2)
- Access (8)
- Peritoneal dialysis (10)
- Biochemical control (0)
- Catheters (3)
- Catheter configuration (0)
- Catheter placement (2)
- Transfer systems (1)
- Dialysate (1)
- Exchange volumes (0)
- Solutions (1)
- Infection - prevention and treatment (4)
- Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients
- Catheter type, placement and insertion techniques for preventing catheter-related infections in chronic peritoneal dialysis patients
- Surgical hand antisepsis to reduce surgical site infection
- Treatment for peritoneal dialysis-associated peritonitis
- Other (1)
- Peritoneal dialysis delivery (1)
- Clearance targets (0)
- Dose / duration (0)
- Treatment options (1)
- General management (33)
- PROCESS OF CARE (9)
- END-OF-LIFE CARE (2)
- END-STAGE KIDNEY DISEASE (0)
- Blood pressure control in haemodialysis patients (0)
- OTHER (6)
- Discharge planning from hospital
- Follow-up services to improve the long-term after-effects of a stay in the intensive care unit
- Improving outcomes for people with multiple chronic conditions
- Interventions to improve people's drug-taking behaviour with lipid-lowering drugs
- Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes
- Shared care across the interface between primary and specialty care in chronic disease management
- SCREENING TESTS (1)
- TRANSPLANTATION (0)
- Medication compliance (0)
- URINARY TRACT INFECTION (0)
- Telephone versus in-office management (0)
- TRANSPLANTATION: KIDNEY (47)
- Acute rejection (3)
- Complications and co-interventions (15)
- Antihypertensive treatment (1)
- Bone and mineral disease (1)
- Cardiovascular risk (3)
- Diabetes (0)
- Infection (8)
- Prevention (6)
- Antifungal agents for preventing fungal infections in solid organ transplant recipients
- Interventions for preventing urinary tract infections in kidney transplant recipients
- Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients
- Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
- Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
- Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
- Treatment (2)
- Prevention (6)
- Nutrition (1)
- Other (1)
- Diagnosis and screening (1)
- Induction therapy / primary immunosuppression (7)
- Antibody therapy (3)
- Antiproliferative agents (1)
- Calcineurin inhibitors (2)
- Target of rapamycin inhibitors (mTOR-I) (1)
- Lifestyle and complimentary therapies (1)
- Maintenance immunosuppression (2)
- Antiproliferative agents (0)
- Calcineurin inhibitors (1)
- Steroids (1)
- Organ donation (1)
- Other (2)
- Transplantation procedures (15)
- Procedural (7)
- Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients
- Cardiac testing for coronary artery disease in potential kidney transplant recipients
- Dressings for the prevention of surgical site infection
- Early versus late removal of urinary catheter after kidney transplantation
- Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury
- Surgical hand antisepsis to reduce surgical site infection
- Interventions for preventing thrombosis in solid organ transplant recipients
- Surgical (8)
- Donors (4)
- Robotic versus laparoscopic versus open nephrectomy for live kidney donors
- Laparoendoscopic single-site donor nephrectomy (LESS-DN) versus standard laparoscopic donor nephrectomy
- Normothermic and hypothermic machine perfusion preservation versus static cold storage for deceased donor kidney transplantation
- Therapeutic donor hypothermia following brain death to improve the quality of transplanted organs
- Recipients (4)
- Donors (4)
- Procedural (7)
- TRANSPLANTATION: KIDNEY-PANCREAS (11)
- Acute rejection (0)
- Complications and co-interventions (5)
- Cardiovascular risk (0)
- Diabetes (0)
- Infection (5)
- Prevention (5)
- Antifungal agents for preventing fungal infections in solid organ transplant recipients
- Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients
- Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
- Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
- Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
- Treatment (0)
- Prevention (5)
- Nutrition (0)
- Diagnosis and screening (1)
- Induction therapy / primary immunosuppression (0)
- Antibody therapy (0)
- Antiproliferative agents (0)
- Calcineurin inhibitors (0)
- Target of rapamycin inhibitors (mTOR-I) (0)
- Maintenance immunosuppression (1)
- Calcineurin inhibitors (0)
- Steroids (1)
- Organ donation (1)
- Other (1)
- Transplantation procedures (2)
- Procedures (2)
- Surgery (0)
- Donors (0)
- Recipients (0)
- TRANSPLANTATION: LUNG (1)
- Acute rejection (0)
- Chronic lung allograft dysfunction (CLAD) (0)
- Lifestyle and complimentary therapies (1)
- TRANSPLANTATION: SOLID ORGAN (23)
- Acute rejection (0)
- Complications and co-interventions (7)
- Cardiovascular risk (0)
- Diabetes (0)
- Infection (6)
- Prevention (6)
- Antifungal agents for preventing fungal infections in solid organ transplant recipients
- Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients
- Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
- Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
- Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
- Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis
- Treatment (0)
- Prevention (6)
- Malignancy (1)
- Nutrition (0)
- Induction therapy / primary immunosuppression (4)
- Antibody induction therapy for lung transplant recipients
- Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients
- Medical interventions to prevent early graft rejection after liver transplantation
- Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients
- Maintenance immunosuppression (2)
- Organ donation (1)
- Other (4)
- Exercise interventions for adults after liver transplantation
- Exercise-based cardiac rehabilitation for patients following a heart transplantation
- Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients
- Synbiotics, prebiotics and probiotics for solid organ transplant recipients
- Prognosis reviews (1)
- Transplantation procedures (4)
- Procedures (2)
- Surgical (2)
- URINARY TRACT INFECTION (29)
- Diagnosis (2)
- Prevention and prophylaxis (10)
- Cranberries for preventing urinary tract infections
- D-mannose for preventing and treating urinary tract infections
- Interventions for preventing recurrent urinary tract infections during pregnancy
- Long-term antibiotics for preventing recurrent urinary tract infection in children
- Methenamine hippurate for preventing urinary tract infections
- Newborn circumcision for the prevention of urinary tract infections in infancy
- Antibiotics for preventing recurrent urinary tract infection in non-pregnant women
- Oestrogens for preventing recurrent urinary tract infection in postmenopausal women
- Probiotics for preventing urinary tract infections in adults and children
- Probiotics for preventing urinary tract infection in people with neuropathic bladder
- Treatment (17)
- Asymptomatic urinary tract infection (3)
- Lower urinary tract infection (12)
- Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women
- Antibiotics for treating lower urinary tract infection in children
- Antimicrobial agents for treating uncomplicated urinary tract infection in women
- Chinese herbal medicine for treating recurrent urinary tract infections in women
- D-mannose for preventing and treating urinary tract infections
- Duration of antibacterial treatment for uncomplicated urinary tract infection in women
- Modes of administration of antibiotics for symptomatic severe urinary tract infections
- Non-steroidal anti-inflammatory drugs for treating symptomatic uncomplicated urinary tract infections in non-pregnant adult women
- Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children
- Cranberries for treating urinary tract infections
- Quinolones for uncomplicated acute cystitis in women
- Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women
- Pyelonephritis (2)
- Urine collection (0)
- Urological and surgical procedures (0)
- UROLOGY (1)
- VESICOURETERIC REFLUX (1)
- Treatment (1)
- VESICOURETERIC REFLUX (1)